Concepedia

Publication | Open Access

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3

DOIFull Paper Access

73

Citations

16

References

2008

Year

Péter Ferenci, H. Brünner, Hermann Laferl, Thomas–Matthias Scherzer, A Maieron, Gabriele Fischer, Harald Hofer, Martin Bischof, Rudolf Stauber, Michael Gschwantler,
Hepatology

Abstract

The results suggest that when administered for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day produce equivalent outcomes in patients infected with HCV genotype 3.

References

YearCitations

Page 1